Skip to main content
main-content

07-06-2022 | EULAR 2022 | Conference coverage | Video

The BE COMPLETE and BE OPTIMAL trials of bimekizumab in PsA

share
SHARE

Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors (6:27).

00:00 Background to the studies 

01:42 Key findings from BE OPTIMAL 

02:59 Key findings from BE COMPLETE 

04:22 How the results compare 

04:43 Bimekizumab safety 

04:55 Relevance for clinical practice

Disclosures

EULAR 2022 Congress coverage

Access the latest news and expert insight from the EULAR 2022 Congress.

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.